mVP Pivotal Protocol Complete and Ready for Submission to FDA
DBV Continues to Engage in Productive Exchanges with FDACash Runway Extended into the First Quarter 2023
The protocol for the new Phase 3 pivotal study of the modified Viaskin Peanut (“mVP”) patch was completed at the end of February 2022 and has been prepared for FDA submission. The Company is currently engaged in fruitful discussions with FDA in preparation for protocol submission and review. DBV expects to complete protocol submission following further alignment with FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.